COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
COLLEGIUM PHARMACEUTICAL, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.01−0.18 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $746.92M
- P/E (TTM)
- 18.6
- Dividend yield
- –
Collegium Pharmaceutical statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Market Cap | $749.11M | $164.85M |
| Enterprise Value | $619.64M | $87.06M |
| PE Ratio | 18.56 | 19.63 |
| PS Ratio | 0.93 | 3.60 |
| PB Ratio | 2.40 | 2.03 |
| P/FCF Ratio | 2.28 | 17.44 |
| P/OCF Ratio | 2.27 | 13.32 |
Enterprise value
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| EV / Sales | 0.77 | 2.43 |
| EV / EBITDA | 3.94 | 14.69 |
| EV / EBIT | 3.94 | 18.47 |
| EV / FCF | 1.89 | 20.97 |
Income (trailing twelve months)
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Revenue | $808.21M | $57.94M |
| Gross Profit | $485.09M | $90.47M |
| Operating Income | $157.44M | -$21.44M |
| Pretax Income | $77.68M | -$14.45M |
| Net Income | $47.92M | -$22.46M |
| EBITDA | $157.44M | -$16.91M |
| EPS (Diluted) | $1.24 | -$0.83 |
Margins
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Gross Margin | 60.0% | 52.3% |
| Operating Margin | 19.5% | -44.5% |
| Pretax Margin | 9.61% | -13.0% |
| Profit Margin | 5.93% | -39.2% |
| EBITDA Margin | 19.5% | -31.3% |
| FCF Margin | 40.6% | -8.85% |
Returns
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Return on Equity (ROE) | 17.6% | -53.1% |
| Return on Assets (ROA) | 2.57% | -41.0% |
| Return on Invested Capital (ROIC) | 100.9% | -32.0% |
| Return on Capital Employed (ROCE) | 10.2% | -37.8% |
Growth
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 14.3% | 6.01% |
| Net Income Growth (YoY) | 32.1% | -37.7% |
| EPS Growth (YoY) | 19.2% | -29.2% |
| FCF Growth (YoY) | 62.7% | 2.34% |
| Revenue Growth (3Y CAGR) | 18.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 20.3% | 6.42% |
| EPS Growth (5Y CAGR) | 17.9% | 3.77% |
Balance sheet
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $129.47M | $62.42M |
| Net Cash (Debt) | $129.47M | $15.68M |
| Net Cash Per Share | $3.98 | $0.66 |
| Equity (Book Value) | $311.91M | $48.79M |
| Book Value Per Share | $9.58 | $1.36 |
| Tangible Book Value | -$1.06B | $23.06M |
| Working Capital | $18.15M | $75.77M |
Financial position
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Current Ratio | 1.03 | 3.30 |
| Quick Ratio | 0.70 | 2.39 |
| Interest Coverage | 2.06 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Operating Cash Flow | $329.92M | -$12.35M |
| Capital Expenditures | -$1.64M | -$1.06M |
| Free Cash Flow | $328.28M | -$20.28M |
| FCF Per Share | $10.08 | -$0.42 |
Efficiency
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Asset Turnover | 0.43 | 0.38 |
| Inventory Turnover | 4.27 | 2.67 |
| Revenue Per Employee | $1.91M | $398.96K |
| Profits Per Employee | $113.27K | -$703.34K |
| Employee Count | 423 | 74 |
Dividends and yields
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Earnings Yield | 6.40% | -22.7% |
| FCF Yield | 43.8% | -9.07% |
Shares
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Shares Outstanding | 32,555,600 | 58,179,650 |
| Shares Change (YoY) | -0.10% | 11.1% |
| Shares Change (QoQ) | 0.28% | 0.54% |
| Float | 31,148,700 | 49,173,100 |
| Shares Held by Insiders | 4.32% | 11.6% |
| Shares Held by Institutions | 121.2% | 59.4% |
Taxes
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Income Tax | $29.77M | $91.50K |
| Effective Tax Rate | 38.3% | 20.6% |
Scores
| Measure | Collegium Pharmaceutical | Industry median |
|---|---|---|
| Graham Number | $16.35 | $17.36 |
| Graham Upside | -28.9% | -43.6% |
| Altman Z-Score | 0.81 | -0.24 |
| Piotroski F-Score | 6 | 4 |
Calculated by StockData from Collegium Pharmaceutical's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.